New parmacological tools

Urodinamica

Volumn 13, Issue 2, 2003, Pages 67-73

  Lazzeri, Massimo ^a,b  

^a Casa di Cura Santa Chiara Firenze ^*  (Italy)

^b Reparto di Urologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BOTULINUM TOXIN; CALCIUM ANTAGONIST; CAPSAICIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; DULOXETINE; ESTROGEN; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROPEPTIDE; NOCICEPTIN; NORADRENALIN UPTAKE INHIBITOR; OXYBUTYNIN; POTASSIUM CHANNEL STIMULATING AGENT; PROPANTHELINE BROMIDE; PROPIVERINE; RESINIFERATOXIN; SEROTONIN UPTAKE INHIBITOR; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; TROSPIUM CHLORIDE; UNINDEXED DRUG; VANILLOID RECEPTOR;

ADRENERGIC SYSTEM; ANIMAL MODEL; BLADDER NECK STENOSIS; CENTRAL NERVOUS SYSTEM; CHOLINERGIC SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DETRUSOR DYSSYNERGIA; DETRUSOR MUSCLE; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; DRUG FORMULATION; ELECTROMOTIVE DRUG ADMINISTRATION; HUMAN; INCONTINENCE; MICTURITION DISORDER; NEUROTRANSMISSION; NONHUMAN; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; STRESS INCONTINENCE; URGE INCONTINENCE;

EID: 0042267264     PISSN: 11205989     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Editorial. Assessment and treatment of urinary incontinence. Lancet 355: 2153-2158, 2000.
2. Voelker R.: International group seeks to dispel incontinence "taboo". JAMA 280: 951, 1998.
3. Kuru M.: Nervous control of micturition. Physiol. Rev. 45: 425-494, 1965.
4. de Groat W.C.: Nervous control of the urinary bladder in the cat. Brain Res. 87: 201-211, 1996.
5. Barrington F.J.: The effect of lesion of the hind and mid brain on micturition in the cat. Q. J. Exp. Physiol. 15: 81-102, 1925.
6. de Groat W.C., Nadelhaft I., Milne R.J., Booth A.M., Morgan C., Thor K.: Organization of the sacral parasympathetic reflex pathways to urinary bladder and large intestine. J. Auton. Nerv. Syst. 3: 135-160, 1981.
7. de Groat W.C., Kawatani M., Hisamitsu T., Cheng C.L., Ma C.P., Thor K., Steers W., Roppolo J.R.: Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J. Auton. Nerv. Syst. 30 (Suppl.): S71-S77, 1990.
8. Jung S.Y., Fraser M.O., Ozawa H., Yokoyama O., Yoshiyama M., De Groat W.C., Chancellor M.B.: Urethral afferent nerve activity affects the micturition reflex; implication for the relationship between stress incontinence and detrusor instability. J. Urol. 162: 204-212, 1999.
9. Yoshimura N., Chancellor M.B.: Current and future pharmacological treatment for overactive bladder. J. Urol. 168: 1897-1913, 2002.
10. Zeegers A.G.M., Kieswetter H., Kramer A.E.J.L., Jonas U.: Conservative therapy of frequency, urgency and urge incontinence: a double-blind clinical trial of flavoxate hydrochloride, oxybutynin chloride, emepronium bromide and placebo. World J. Urol. 5: 57, 1987.
11. Yarker Y.E., Goa K.L., Fitton A.: Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 6: 243, 1995.
12. Versi E., Appell R., Mobley D., Patton W., Saltzstein D.: Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet. Gynecol. 95: 718, 2000.
13. Abrams P., Freeman R., Anderstroöm C., Mattiasson A.: Tolterodine, a new antimuscarinic agent as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br. J. Urol. 81: 801, 1998.
14. Van Kerrebroeck P., Kreder K., Jonas U., Zinner N., Wein A.: Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 57: 414, 2001.
15. Rosario D.J., Cutinha P.E., Chapple C.R.: The effects of single-dose darifenacin on cystometric parameters and salivary flow in patients with urge incontinence secondary to detrusor instability. Eur. Urol. 30: 240, 1996.
16. Stohrer M., Bauer P., Giannetti B.M., Richter R., Burgdorfer H., Murtz G.: Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial. Urol. Int. 47: 138, 1991.
17. Di Stasi S.M., Giannantoni A., Navarra P., Capelli G., Storti L., Porena M., Stephen R.L.: Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin. J. Urol. 166: 2232-2236, 2001.
18. Woods M., Carson N., Norton N.W., Sheldon J.H., Argentieri T.M.: Efficacy of the b3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat. J. Urol. 166: 1142, 2001.
19. Maggi C.A., Barbanti G., Santiccioli P., Beneforti P., Misuri D., Meli A., Turini D.: Cystomanometric evidence that capsaicin-sensitive nerves modulate the afferent branch of micturition reflex in humans. J. Urol. 142: 150-154, 1989.
20. Fowler C.J., Beck R.O., Gerrard S., Betts C.D., Fowler C.G.: Intravesical capsaicin for the treatment of detrusor hyperreflexia. J. Neurol. Neurosurg. Psychiatry 57: 169-172, 1994.
21. De Ridder D., Chandiramani V., Dasgupta P., Van Poppel H., Baert L., Fowler C.J.: Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term follow-up. J. Urol. 158: 2087-2092, 1997.
22. Lazzeri M., Spinelli M., Beneforti P., Zanollo A., Turini D.: Urodynamic assessment during intravesical infusion of capsaicin for the treatment of refractory detrusor hyperreflexia. Spinal Cord 37: 440-443, 1999.
23. Petersen T., Nielsen J.B., Schroder H.D.: Intravesical capsaicin in patients with detrusor hyperreflexia: a placebo-controlled cross-over study. Scand. J. Urol. Nephrol. 33: 104-110, 1999.
24. Lazzeri M., Beneforti P., Benaim G., Turini D.: Urodynamic effects of intravesical resiniferatoxin in humans: Preliminary results. Proceedings of the Italian Urodynamics Society, 20th annual meeting - Salsomaggiore - Urodinamica 6: 107-109, 1996.
25. Rivas D.A., Shenot P.J., Vasavada S.P., Quinn D., Hubert C., Green B., Kennelly M., Rickson J., Kim D.Y., de Groat W.C., Chancellor M.B.: Intravesical resiniferatoxin (RTX) improves bladder capacity and decreases incontinence in patients with refractory detrusor hyperreflexia (DH): a multicenter, blinded randomized, placebo-controlled trial. J. Urol. 163 (Suppl.): 1086, 2000.
26. Lazzeri M., Spinelli M., Zanollo A., Turini D.: Intravesical vanilloids and neurogenic incontinence: 10 years of experience. Urodinamica 13: 9-14, 2003.
27. Lecci A., Giuliani S., Garret C., Maggi C.A.: Evidence for a role of tachykinins as sensory transmitters in the activation of micturition reflex. Neuroscience 54: 827, 1993.
28. Lecci A., Giuliani S., Santicioli P., Maggi C.A.: Involvement of spinal tachykinin NK1 and NK2 receptors in detrusor hyperreflexia during chemical cystitis in anaesthetized rats. Eur. J. Pharmacol. 259: 129, 1994.
29. Lecci A., Giuliani S., Meini S., Maggi C.A.: Nociceptin and the micturition reflex. Peptides 21: 1007-1021, 2000.
30. Calo G., Guerrini R., Rizzi A., Salvadori S., Regoli D.: Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br. J. Pharmacol. 129: 1261-1283, 2000.
31. Lecci A., Giuliani S., Meini S., Maggi C.A.: Nociceptin and the micturition reflex. Peptides 21: 1007-1021, 2000.
32. Lazzeri M., Calò G., Spinelli M., Guerrini R., Salvadori S., Beneforti P., Sandri S., Regoli D., Turini D.: Urodynamic effects of intravesical nociceptin/orphanin fq in neurogenic detrusor overactivity - a randomized, placebo-controlled, double-blind study. Urology (in press).
33. Thor K.B., Katofiasc M.A.: Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J. Pharmacol. Exp. Ther. 274: 1014, 1995.
34. Norton P.A., Zinner N.R., Yalcin I., Bump R.C.: Duloxetine versus placebo in the treatment of stress urinary incontinence. Am. J. Obstet. Gynecol. 187: 40-48, 2002.
35. Grazko M.A., Polo K.B., Jabbari B.: Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 45: 712, 1995.
36. Jankovic J., Schwartz K., Donovan D.T.: Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J. Neurol. Neurosurg. Psychiatry 53: 633, 1990.
37. Schurch B., Stohrer M., Kramer G., Schmid D.M., Gaul G., Hauri D.: Botulinum toxin A for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J. Urol. 164: 692-697, 2000.
38. Reitz A., Von Tobel J., Stohrer M., Kramer G., Del Popolo G., Pannek J., Chartier-Kastler E., Ricther R., Burgdorger H., Haferkamp A., Madersbacher H., Schurch B.: European experience of 184 cases treated with botulinum-A toxin injections into the detrusor muscle for neurogenic incontinence. Proceedings of the Italian Society of Urodynamics, 26 Annual Meeting, Sorrento, 24-26 October 2002.
39. De Francesco O.: Tossina Botulinica nell'iperriflessia detrusoriale. XIII Corso Monotematico SIUD, 29-30 November, Magenta, 2002.